Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8Z33

Crystal Structure of HIF-PHD2 in complex with compound 4

これはPDB形式変換不可エントリーです。
8Z33 の概要
エントリーDOI10.2210/pdb8z33/pdb
関連するPDBエントリー8Z31 8Z32
分子名称Egl nine homolog 1, FE (II) ION, FLUORIDE ION, ... (5 entities in total)
機能のキーワードrenal anemia, inhibitor, oxidoreductase
由来する生物種Homo sapiens (human)
タンパク質・核酸の鎖数2
化学式量合計56481.66
構造登録者
Ito, S.,Baba, D.,Fukuda, T.,Tanaka, N. (登録日: 2024-04-14, 公開日: 2025-02-26)
主引用文献Fukuda, T.,Kuribayashi, T.,Takano, R.,Sasaki, K.,Tsuji, T.,Niitsu, Y.,Ishii, K.,Hashimoto, M.,Baba, D.,Ito, S.,Tanaka, N.
Discovery of DS44470011: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia.
Bioorg.Med.Chem.Lett., 108:129799-129799, 2024
Cited by
PubMed Abstract: Inhibition of the hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) represents a promising strategy for discovering next-generation treatments for renal anemia. We identified a pyrimidine core with HIF-PHD inhibitory activity based on scaffold hopping of FG-2216 using crystal structures of HIF-PHD2 in complex with compound. By optimizing the substituents at the 2- and 6- positions of the pyrimidine core, we discovered DS44470011, which improves the effectiveness of erythropoietin (EPO) release in cells. Oral administration of DS44470011 to cynomolgus monkeys increased plasma EPO levels.
PubMed: 38754564
DOI: 10.1016/j.bmcl.2024.129799
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.6 Å)
構造検証レポート
Validation report summary of 8z33
検証レポート(詳細版)ダウンロードをダウンロード

252456

件を2026-04-22に公開中

PDB statisticsPDBj update infoContact PDBjnumon